morning name grace conference operator today time would like welcome everyone merck sale earn conference call operator instruction thank would like turn call vice president investor relation please ahead vice president investor relation thank grace good morning welcome merck first quarter conference call speak today call president chief executive officer chief financial officer president merck research start like point item item result acquisition relate charge restructure certain item note exclude item result provide reconciliation press release would like remind statement make today consider forward look statement within mean safe harbor provision private security litigation reform statement make base current belief merck management subject significant risk uncertainty underlie assumption prove inaccurate uncertainty materialize actual result differ materially forth forward look statement file include item identify certain risk factor cautionary statement could cause company actual result differ materially project forward look statement make morning merck undertake obligation publicly update forward look statement today call slide presentation accompany speaker prepare remark presentation today earn release file post investor relation section merck website like turn call president thank good morning thank join today call start take moment speak ongoing crisis hopeful immediate peaceful resolution basin country support people stand recognize terrible tragedy represent merck make every effort protect health safety employee ensure essential medicine vaccine continue reach patient addition dedicate meaningful resource address humanitarian crisis country multiple channel turn business continue deliver across strategic priority first quarter sustain strong business momentum deliver robust bottom line growth also achieve significant clinical advancement across research pipeline successfully integrate move result strong start achieve strong bottom line growth commercially continue execute across broad growth driver notably animal health performance reflect robust underlie demand derisked innovative portfolio reinforce importance science lead strategy antiviral treatment significant contributor even exclude sale line growth still versus last year accelerate broad global access establish important tool patient healthcare provider address ongoing pandemic since receive emergency authorization deliver approximately million course country success achieve reflect update guidance demonstrate expectation another year strong growth overall business momentum oncology business benefit continue rollout important indication include earlier line therapy global demand remain strong growth benefit increase supply result significant investment make expand manufacture capacity animal health business remain position grow market rate longer term remain confident ability deliver strong revenue growth operate margin expansion prepare post period continue strengthen lever build upon order deliver long term growth oncology remain commit build foundational position achieve expand presence therapeutic area establish endure leadership position addition continue maximize opportunity durable growth driver pneumococcal portfolio animal health prove commercial execution beyond exist portfolio business development remain priority remain highly focus pursuit best external innovation appropriately aggressive great science value align strong track record business development know need believe position quickly deploy capital toward right strategic asset present finally continue advance broad pipeline across therapeutic area order deliver medically important innovation patient take important step provide increase transparency opportunity portfolio business include recent investor event earlier month provide detail description grow cardiovascular portfolio pipeline merck focus effort need greatest best opportunity positively impact patient life include heart failure pulmonary arterial hypertension thrombosis atherosclerosis make significant advancement across pipeline believe broad differentiate portfolio meaningful impact patient life least eight potential approval confident important innovation potential meaningful growth driver merck next decade host inaugural event highlight activity four priority area access health employee environmental sustainability ethic value effort ground company value look forward build merck legacy operate responsibly forward close like take moment recognize announce retirement eight year merck instrumental help merck become lead oncology company particularly leadership development wish best future endeavor confident behind outstanding program please report appoint succeed deep experience serve several research capacity throughout decade merck also unwavering commitment patient consistent merck purpose save improve life summary begin strong operational momentum want express sincere thank employee worldwide continue commitment remain confident fundamental strategy growth prospect ability deliver significant benefit patient value shareholder future turn call chief financial officer thank good morning highlight strong start exceptional performance revenue earn result demonstrate focus science innovation core strategy enable excellent execution dedicate colleague across globe deliver value patient customer investor total company revenue billion increase contribute billion revenue exclude base business deliver strong growth remainder comment exchange basis human health business continue strong momentum exclude human health business grow drive primarily pillar reduce impact pandemic animal health business also deliver market performance sale increase drive growth across companion animal livestock segment turn first quarter performance brand oncology grow billion reflect continue robust global demand expansion indication continue demonstrate strong growth across tumor benefit recent launch earlier stage cancer include triple negative breast renal cell carcinoma melanoma currently approve treat five indication earlier stage cancer excite potential opportunity expand adjuvant lung cancer base encourage data keynote continue confident robust clinical data combine physician familiarity experience product support expand patient benefit early stage disease metastatic continue maintain leadership position small cell lung cancer capture eligible patient outside growth continue drive lung cancer ongoing launch head neck cancer renal cell carcinoma remain market lead inhibitor alliance revenue grow drive uptake metastatic breast cancer also excite expand opportunity early stage breast cancer follow recent approval base study look forward potentially reach broad prostate population base propel study alliance revenue also strong growth drive uptake follow launch keynote advance renal cell carcinoma keynote metastatic endometrial cancer encourage patient share trend across tumor type growth also benefit increase demand hepatocellular carcinoma certain onetime item also excite launch patient certain associate tumor continue generate strong interest among scientific leader provider patient although still early launch strong uptake provide treatment option significant unmet need patient work potentially extend reach broader indication future vaccine portfolio deliver excellent performance lead increase billion outside significant growth drive strong underlie demand across geography particularly increase supply sale increase time practice global demand remain robust support strong clinical real world data effort increase recognition vaccine help prevent certain relate cancer female male acute care portfolio sale grow drive ongoing recovery surgical procedure quarter continue strong leadership neuromuscular blockade reversal agent class animal health business deliver another quarter robust growth sale increase companion animal sale increase drive global demand parasiticides include line product vaccine livestock sale increase higher demand ruminant poultry walk remainder comment basis gross margin decrease percentage point drive primarily higher sale reminder share profit equally partner reflect within sale reduce gross margin percentage gross margin quarter also reflect favorable impact product offset higher manufacture operate expense increase billion continue prudently invest behind growth driver pipeline expense approximately million rate take together earn share turn guidance reminder request certain company industry include make change report longer exclude significant expense upfront milestone payment relate collaboration license agreement transaction account asset acquisition result result billion charge primarily relate acquisition include recast result increase expense billion decrease impact first quarter guidance assume significant transaction would previously exclude could change future quarter execute business development strategic priority underlie strength business enable raise narrow full year guidance expect revenue billion billion represent growth exclude impact foreign exchange project impact foreign exchange include incremental headwind approximately million rate result full year negative impact increase gross margin expectation expect operate expense billion billion midpoint consistent imply prior guidance expect expense approximately million assume full year rate increase estimate foreign income assume billion share outstanding take together increase expect range represent pull operational strength pillar operate expense leverage offset part slight reduction sale assumption increase rate incremental headwind foreign exchange rate consider model area focus first narrow range full year guidance billion billion enter supply purchase agreement approximately million course therapy since authorization deliver million course therapy include million first quarter expect approximately half remain full year revenue second quarter continue expect strong annual growth especially market include finally reminder revenue line contain several item include supply sale begin record upon completion spin last year vaccine also include revenue hedge royalty revenue first quarter also benefit approximately million receipt relate license agreement capital allocation priority remain unchanged first continue prioritize investment business pipeline drive near long term growth continue appropriately aggressive augment internal pipeline strategic business development intend pursue additional value enhance opportunity remain commit dividend goal increase time extent excess cash return shareholder share repurchase conclude remain confident growth business drive global demand innovative medicine vaccine position financial operational strength continue execution enable deliver value patient shareholder future like turn call president merck research thank good provide update progress first quarter continue demonstrate progress pipeline make advance across multiple therapeutic area include oncology advance earlier stage cancer cardiovascular disease vaccine also provide update oncology continue build upon strong position execute strategy expand deepen extend benefit patient diversify imprint cancer past quarter achieve milestone several tumor type different stage disease notably continue expand treatment impact earlier stage disease approval five society medical oncology virtual session last month data keynote pearl trial evaluate adjuvant treatment patient stage small cell lung cancer follow surgical resection present interim analysis significantly improve disease free survival study dual primary endpoint trial continue analyze dual primary endpoint disease free survival patient whose tumor express high level meet statistical significance time plan interim analysis latest data provide strong signal benefit adjuvant treatment study additional ongoing study earlier stage small cell lung cancer include keynote evaluate neoadjuvant adjuvant therapy patient disease keynote study stereotactic body radiotherapy without adult stage disease study combination stage disease follow approval adjuvant treatment patient year older stage melanoma follow complete resection base keynote announce prespecified interim analysis study also meet secondary endpoint distinct metastasis free survival show continue improvement recurrent free survival compare placebo data keynote reinforce evidence adjuvant therapy appropriate patient stage follow surgery help prevent recurrence disease similarly earlier stage along announce approve adjuvant treatment patient germline patient negative high risk early breast cancer previously treat chemotherapy either surgery base study woman cancer receive approval treatment patient microsatellite instability high mismatch repair deficient advance endometrial carcinoma base data keynote approval fourth gynecologic cancer approval mark fifth approval derive keynote trial innovative trial design evaluate predictive tumor biomarkers patient receive advance solid tumor next prostate cancer along positive result present society clinical oncology cancer symposium propel trial evaluate combination first line treatment patient metastatic cast resistant prostate cancer without mutation group therapy plan interim analysis result show improvement radiographic progression free survival versus standard care early result also show trend toward improve overall survival trial continue secondary endpoint plan engage health authority find bring important option appropriate patient prostate cancer represent significant unmet need continually gain important insight biology tumor keen make impact patient late stage disease last month announce discontinuation study evaluate combination treatment metastatic castrate resistant prostate cancer interim analysis study show evidence superiority enzalutamide respect overall survival radiographic progression free survival attention metastatic castrate resistant prostate cancer shift keynote study explore combination chemotherapy keynote evaluate nomination enzalutamide outside unite state continue deliver regulatory strategy notable action include positive opinion cervical high early stage breast cancer approval combination regimen plus advance renal cell carcinoma finally coincide early plan host investor event recent cardiovascular investor event showcased grow portfolio program target range condition include atherosclerosis heart failure pulmonary arterial hypertension thrombosis follow completion acquisition make strong progress advance development potential first class valuable receptor type fusion protein recently complete enrollment stellar trial ahead schedule stellar first four ongoing phase study evaluate sotatercept progress reflect enthusiasm investigator regard novel investigational mechanism first time heart association college cardiology heart failure society guideline management heart area include collaborate partner class recommendation treatment stage heart failure reduce ejection fraction guideline highlight mechanism potential benefit stimulate cyclase increase base evidence pioneer trial first drug specifically study approve patient worsen heart failure drug recommend guideline patient ongoing study design expand evidence date evaluate patient chronic heart failure reduce ejection fraction experience recent worsen heart failure event merck uniquely position meaningfully impact treatment patient cardiovascular disease least eight potential approval include stable heart failure sotatercept pipeline candidate include entail soluble cyclase stimulator factor inhibitor oral inhibitor next pandemic evolve continue regional surge infection rate emergence variance strain resistant specific monoclonal antibody regimen appear able evade vaccine protection highlight importance test availability antiviral option recent congress clinical microbiology infectious disease present phase virology outcome data move grow body evidence antiviral property panoramic trial evaluate novel antiviral early treatment sponsor university fund government move trial evaluate post exposure prophylaxis ongoing work collaboratively medicine agency provide additional data trial order secure approval remain confident safety efficacy appropriate patient particular believe propensity drug drug interaction make important option patient next program earlier month extend date supplemental biologics license application valent conjugate vaccine infant child agency request additional analysis data provide importantly study request also program receive breakthrough therapy designation investigational design target serotypes responsible approximately residual invasive disease older adult population include eight unique serotypes currently license vaccine look forward provide deeper update close would like thank many contribution merck past eight year build upon legacy constantly remind wisdom teach grateful work remarkable train mentor course experience commitment merck purpose save improve life make ideal leader global clinical development program wealth experience hold leadership role across array therapeutic area year merck include vaccine infectious disease oncology look forward continue partner build upon merck legacy innovation breakthrough size back vice president investor relation thank grace could please begin operator instruction thank